Satadru S. Mandal,
Guochao Liao and
Zhongwu Guo*
Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, Michigan 48202, USA. E-mail: zwguo@chem.wayne.edu; Tel: +1-313-577-2557
First published on 24th February 2015
A derivative of the tumor-associated globo H antigen, a complex hexasaccharide, was synthesized by a convergent and efficient [3 + 2 + 1] strategy using various glycosylation methods. All glycosylation reactions afforded good to excellent yields and outstanding stereoselectivity, including the installation of cis α-linked D-galactose and L-fucose. The longest linear sequence for this synthesis was 11 steps from a galactose derivative 11 to give an overall yield of 2.6%. The synthetic target had a free and reactive amino group at the glycan reducing end, facilitating its conjugation with other molecules for various applications.
Globo H was first assembled by Danishefsky and co-workers using the glycal strategy,14,15 which was subsequently refined.16 Other elegant syntheses include Schmidt's synthesis based on trichloroacetimidate glycosylation,17 Boon's synthesis employing a two-directional glycosylation strategy,18 Wong's reactivity based one-pot synthesis,19,20 Huang's thioglycoside pre-activation based one-pot synthesis,21 Wang's enzymatic synthesis,22 and Seeberger's linear and solid-phase syntheses,23,24 as well as the synthesis of globo H fragments.25,26 In spite of the great progress in total synthesis of globo H, currently it is still difficult to access, especially in the form suitable for further elaborations, thus scientist has to rely on oneself to prepare it for any investigation. As a consequence, new synthetic strategies for globo H are still desirable.
In an effort to explore TACA-based anticancer vaccines, we describe herein an efficient synthesis for a globo H derivative 2 (Scheme 1), which carried a free amino group at the glycan reducing end. It would facilitate the conjugation of this carbohydrate antigen with other molecules, such as vaccine carriers like KLH or monophosphoryl lipid A derivatives – a new type of vaccine carriers that are being explored in our laboratory,27,28 through simple linkers that do not have ill influence on the immunological properties of the resultant glycoconjugates.29 This synthesis is highlighted by combined application of different glycosylation methods to effect the assembly of specific glycosidic linkages.
The project commenced with the development of a new, concise and efficient route for the synthesis of 730 and 931,32 (Scheme 2), using 1133,34 as the common intermediate prepared from free D-galactose via a series of conventional reactions including peracetylation, thioglycosylation, deactylation, and regioselective acetal formation at the 4,6-O-positions. In both syntheses, a key step was the tin complex directed regioselective alkylation to give 3-O-alkylated products 12 and 13. Benzoylation of 12 readily afforded glycosyl donor 7. On the other hand, benzylation of 13 followed by oxidative hydrolysis of the thioglycoside in 14 and then trichloroacetimidation of the resultant hemiacetal gave glycosyl donor 9 (α
:
β 12
:
1) in an excellent overall yield (42%) from 11.
The synthesis of the disaccharide building block 10 (Scheme 3) started from lactose which was first converted into 15 according to a literature procedure.35,36 Selective protection of the cis 4′-O- and 6′-O-postions in 15 with the benzylidene ring was carried out successfully by treating 15 with benzaldehyde dimethyl acetal and camphor sulfonic acid (CSA) to afford 16 in a 74% yield. Perbenzylation of the remaining free hydroxyl groups in 16 was followed by regioselective reductive ring opening of the 4′:6′-O-benzylidene acetal in the resultant 17 to expose the 4′-OH and offer the desired building block 10 smoothly.
To construct the disaccharide building block 5 (Scheme 4), we conducted the glycosylation of 8, which was prepared from galactosamine by a reported procedure,30 with 7 at −5 °C in dichloromethane using methyl trifluoromethanesulfonate (MeOTf) as the promoter. While TLC indicated that the reaction was clean, to our surprise, it gave the unwanted α-disaccharide 18 as the predominant product (α
:
β 9
:
1), in spite of the presence of a participating Bz group at the 2-O-position of 7. A potential explanation for this result was that the presence of benzylidene rings in the donor and acceptor somehow decreased their reactivities to facilitate SN2 type of reaction. To deal with the problem, we converted thioglycoside donor 7 into the more reactive tricholoroacetamediate 19 in two steps, including treating 7 with N-iodosuccinimide (NIS) and silver triflate (AgOTf) in wet dichloromethane and then with trichloroacetonitrile in the presence of 1,8-diazabicycloundec-7-ene (DBU) to get mainly α-imidate (α
:
β 12
:
1). Glycosylation of 8 with 19 proceeded smoothly in the presence of trimethyl trifluoromethanesulfonate (TMSOTf) to give the desired β-disaccharide 4 (JH-1′,H-2′ = 8.1 Hz) as the major product (α
:
β 1
:
10) in a good yield (75%). Then, we attempted to selectively remove the 2′-O-benzoyl group in 5 using sodium methoxide in methanol, hoping that the fucose residue could be introduced at this stage to obtain a trisaccharide fragment for the target hexasaccharide assembly by a highly convergent [3 + 3] strategy. Surprisingly, the reaction was complex even when only a catalytic amount of sodium methoxide was used. It was possible that the Phth group was affected under this condition. Consequently, we directly employed 5 as a glycosyl donor for the assembly of the target molecule by a [3 + 2 + 1] strategy.
Next, our attention was focused on the installation of Gal III α-linked to Gal II (Scheme 5), which was one of the major challenges in the synthesis of globo H antigen, because in general it is relatively difficult to create the cis α-galactosidic linkage and the galactose axial 4-OH shows relatively low nucleophilicity. To cope with this issue, in addition to using the nonparticipating Bn group for 2-O-protection in donor 9, we also executed the glycosylation reaction employing a unique experimental procedure of reversed addition, i.e., slowly adding donor 9 to the solution of acceptor 10 and promoter TMSOTf at −70 °C. The reaction afforded the desired α-trisaccharide 6 (JH-1′′,H-2′′ = 3.2 Hz) in a good yield (58%) and excellent stereoselectivity (α
:
β 15
:
1). Selective removal of the 3′′-O-para-methoxybenzyl (PMB) group in 6 with DDQ gave trisaccharide 20 as a glycosyl acceptor in an 86% yield.
The coupling reaction between 5 and 20 was accomplished smoothly in CH2Cl2 at −30 °C with NIS and AgOTf as promoters. The reaction was stereospecific to generate the β-anomer 3 only (JH-1′′′,H-2′′′ = 7.8 Hz), probably due to the participation of the neighboring 2-N,N-Phth group in donor 5 in the glycosylation. Again, attempts to selectively remove the Bz group at the Gal V 2-O-position in 3 were unsuccessful. Therefore, we decided to remove the 2-N,N-Phth protection and install the desired N-acetyl group at this stage, instead of at the final global deprotection step, and concomitantly remove the 2′′′′-O-Bz group. Refluxing 3 with hydrazine hydrate (NH2NH2·H2O) in ethanol removed the Phth and Bz groups smoothly and cleanly (monitored by TLC and MS). The freed amino group and hydroxyl group were acetylated under routine conditions, which was followed by selective removal of the 2′′′′-O-acetyl group with sodium methoxide in methanol to give 21 as a glycosyl acceptor. Finally, fucosylation of 21 with thioglycoside donor 426,37 using NIS and TfOH as promoters resulted in stereospecific formation of the desired hexasaccharide 22 (JH-Fuc-1,2 = 3.7 Hz) in a good yield (70%). We also transformed 4 into its corresponding trichloroacetimidate and tested it as a donor to react with acceptor 3 using TMSOTf as promoter; however, this reaction gave the desired hexasaccharide 22 in a very poor yield (15%). Clearly, the results of a glycosylation extensively depend on the donors used in the reaction. Attempted global deprotection of 22 to remove all of the benzylidene and Bn groups in one step by hydrogenolysis gave rather complex results, and the main side reactions were partial debenzylidenation as noticed by MS analysis. Consequently, we switched to a two-step protocol for the global deprotection, including the removal of all benzylidene groups in acetic acid and water (5
:
1) at 60 °C and then hydrogenolysis to remove all of the Bn groups with concomitant reduction of the azido group to a free primary amine, to yield the target molecule 2, which was fully characterized with both 1D, 2D NMR and HR MS.
In conclusion, a convergent and highly efficient [3 + 2 + 1] strategy was developed for the synthesis of a derivative of the globo H antigen. Different glycosylation methods were explored for generating the glycosidic linkages, so as to establish optimal conditions for the synthesis. As a consequence, all of the glycosylation reactions offered good to excellent yields and outstanding stereoselectivity, including the reactions to install the rather challenging cis α-linked D-galactose and L-fucose. Eventually, the target molecule 2 was prepared from a galactose derivative 11 in 11 steps and a 2.6% overall yield, which represented the longest linear synthetic sequence. The good overall yield of the current synthesis would make it feasible to prepare the title compound in relatively large quantities. Moreover, the target molecule 2 carried a free amino group at the glycan reducing end that can be selectively elaborated in the presence of free hydroxyl groups. It would facilitate regioselective conjugation of 2 with other molecules, thus it can be useful for various biological studies and applications.
:
9, v/v) to produce 12 (4.28 g, 83%) as colorless syrup. 1H NMR (400 MHz, CDCl3): δ 7.58–7.54 (m, 2H, ArH), 7.40–7.35 (m, 8H, ArH), 5.45 (s, 1H, CHPh), 4.77 (s, 2H, CH2Ph), 4.36 (d, J = 9.6 Hz, 1H, H-1), 4.31 (dd, J = 12.0, 1.6 Hz, 1H, H-6), 4.18 (d, J = 2.4 Hz, 1H, H-4), 4.07 (t, J = 9.6 Hz, 1H, H-2), 3.97 (dd, J = 12.0, 1.6 Hz, 1H, H-6′), 3.50 (dd, J = 9.6, 4.0 Hz, 1H, H-3), 3.41 (s, 1H, H-5), 2.89–2.69 (m, 2H, SCH2CH3), 2.58 (bs, 1-OH), 1.33 (t, J = 7.6 Hz, 3H, SCH2CH3); 13C NMR (100 MHz, CDCl3): δ 138.0, 133.3, 130.2, 128.5, 128.0, 127.9, 126.8, 101.6, 83.1, 78.3, 73.7, 71.3, 70.4, 69.7, 69.0, 23.0, 15.1.
:
10, v/v). 1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 6.5 Hz, 2H, ArH), 7.62–7.54 (m, 3H, ArH), 7.50–7.44 (m, 2H, ArH), 7.42–7.35 (m, 3H, ArH), 7.27–7.16 (m, 5H, ArH), 5.74 (t, J = 9.7 Hz, 1H, H-2), 5.52 (s, 1H, CHPh), 4.66 (q, J = 12.9 Hz, 2H, CH2Ph), 4.55 (d, J = 9.7 Hz, 1H, H-1), 4.36 (d, J = 12.9 Hz, 1H, H-6), 4.28 (d, J = 3.2 Hz, 1H, H-4), 4.02 (d, J = 12.9 Hz, 1H, H-6′), 3.75 (dd, J = 9.7, 3.2 Hz, 1H, H-3), 3.47 (s, 1H, H-5), 2.98–2.87 (m, 1H, SCH2CH3), 2.82–2.72 (m, 1H, SCH2CH3), 1.28 (t, J = 6.5 Hz, 3H, SCH2CH3); 13C NMR (100 MHz, CDCl3): δ 165.3, 137.8, 137.7, 129.9, 129.1, 128.3, 128.2, 127.8, 127.7, 126.5, 101.4, 73.4, 71.0, 70.1, 69.4, 68.7, 22.7, 14.9; HRMS (ESI TOF): calcd for C29H30NaO6S [M + Na]+ m/z, 529.1661; found, 529.1668.
:
4, v/v) to afford the hemiacetal as a white solid (1.38 g, 76%, an anomeric mixture with α as the major product), which was directly applied to the next reaction. DBU (4 drop) was added to a solution of the above product (1.3 g, 2.8 mmol) and trichloroacetonitrile (1.1 mL, 14.05 mmol) in anhydrous CH2Cl2 (15 mL), and the solution was stirred under an Ar atmosphere at 0 °C for 1 h. The reaction mixture was concentrated in vacuum, and the product was purified with a Et3N neutralized silica gel column to get 19 (1.42 g, 81%) as a white solid. 1H NMR (400 MHz, CDCl3): δ 8.49 (s, 1H, –NH), 7.79 (d, J = 8.1 Hz, 2H, ArH), 7.61–7.54 (m, 3H, ArH), 7.46–7.35 (m, 5H, ArH), 7.34–7.29 (m, 2H, ArH), 7.28–7.23 (m, 3H, ArH), 6.77 (d, J = 3.2 Hz, 1H, H-1), 5.74 (dd, J = 11.3, 3.2 Hz, 1H, H-2), 5.58 (s, 1H, CHPh), 4.74 (q, J = 12.9 Hz, 2H, CH2Ph), 4.43 (d, J = 3.2 Hz, 1H, H-4), 4.34 (d, J = 12.9 Hz, 1H, H-6), 4.28 (dd, J = 11.3, 3.2 Hz, 1H, H-3), 4.08 (d, J = 12.9 Hz, 1H, H-6′), 3.94 (s, 1H, H-5); 13C NMR (100 MHz, CDCl3): δ 165.6, 160.4, 137.5, 137.4, 133.3, 129.8, 129.4, 129.2, 128.4, 128.38, 128.32, 128.1, 128.0, 126.4, 101.2, 95.0, 73.6, 72.6, 71.7, 69.2, 68.9, 65.4.
:
11, v/v) to obtain 14 (4.38 g, 81%) as colorless syrup. 1H NMR (400 MHz, CDCl3): δ 7.56 (d, J = 6.5 Hz, 2H, ArH), 7.48–7.26 (m, 10H, ArH), 6.86 (d, J = 8.1 Hz, 2H, ArH), 5.49 (s, 1H, CHPh), 4.88 (q, J = 12.9 Hz, 2H, CH2Ph), 4.71 (s, 2H, CH2Ph), 4.45 (d, J = 9.7 Hz, 1H, H-1), 4.31 (d, J = 11.3 Hz, 1H, H-6), 4.14 (d, J = 3.2 Hz, 1H, H-4), 3.97 (d, J = 11.3 Hz, 1H, H-6′), 3.89 (t, J = 9.7 Hz, 1H, H-2), 3.81 (s, 3H, –OCH3), 3.59 (dd, J = 9.7, 3.2 Hz, 1H, H-3), 3.35 (s, 1H, H-5), 3.93–3.83 (m, 1H, SCH2CH3), 3.82–3.72 (m, 1H, SCH2CH3), 1.35 (t, J = 6.5 Hz, 3H, SCH2CH3); 13C NMR (100 MHz, CDCl3): δ 159.3, 138.4, 138.0, 130.3, 129.4, 129.1, 128.4, 128.3, 128.2, 127.7, 127.6, 126.6, 113.8, 101.5, 84.4, 80.7, 76.9, 75.7, 74.0, 71.4, 69.8, 69.4, 55.3, 23.8, 15.1; HRMS (ESI TOF): calcd for C30H34NaO6S [M + Na]+ m/z, 545.1974; found, 545.1972.
:
9, v/v) to give 16 as a white floppy solid (3.74 g, 74.2%). 1H NMR (400 MHz, CDCl3): δ 7.55–7.50 (m, 2H, ArH), 7.38–7.31 (m, 3H, ArH), 5.61 (s, 1H, CHPh), 4.48 (d, J = 7.8 Hz, 1H, H-1), 4.35 (d, J = 7.8 Hz, 1H, H-1′), 4.23–4.12 (m, 3H, H-6a′, H-4′, H-6b′), 4.03–3.97 (m, 1H, H-6b), 3.92–3.89 (m, 2H, H-4, OCH2CH2N3), 3.77–3.70 (m, 1H, OCH2CH2N3), 3.68–3.55 (m, 4H, H-3, H-6a, H-3′, H-5′), 3.49–3.40 (m, 3H, H-2, OCH2CH2N3), 3.34 (bs, –OH), 3.32–3.25 (m, 2H, H-2′, H-5); 13C NMR (100 MHz, CDCl3): δ 138.1, 128.5, 127.6, 126.1, 103.4, 102.9, 100.8, 78.6, 75.9, 75.1, 74.8, 73.4, 72.1, 70.3, 68.8, 68.0, 66.9, 60.3, 50.6.
:
10, v/v) of the condensed product. 1H NMR (400 MHz, CDCl3): δ 7.76–7.19 (m, 30H, aromatic), 5.48 (s, 1H, CHPh), 5.21 (d, J = 10.8 Hz, 1H, CH2Ph), 4.94 (d, J = 11.0 Hz, 1H, CH2Ph), 4.87 (d, J = 11.2 Hz, 1H, CH2Ph), 4.83–4.73 (m, 5H, CH2Ph), 4.56 (d, J = 12.2 Hz, 1H, CH2Ph), 4.48 (d, J = 7.8 Hz, 1H, H-1), 4.44 (d, J = 7.8 Hz, 1H, H-1′), 4.34 (d, J = 12.0 Hz, 1H, CH2Ph), 4.22 (d, J = 12.2 Hz, 1H, H-6b′), 4.09–4.03 (m, 2H, H-4, H-6b), 3.99 (t, J = 9.0 Hz, 1H, H-6a′), 3.92–3.84 (m, 2H, H-4′, OCH2CH2N3), 3.78 (t, J = 9.3 Hz, 1H, H-2), 3.76–3.69 (m, 2H, H-6a, OCH2CH2N3), 3.36 (t, J = 9.0 Hz, 1H, H-2′), 3.56–3.36 (m, 5H, H-3, H-5, H-3′, OCH2CH2N3), 2.96 (s, 1H, H-5′); 13C NMR (100 MHz, CDCl3): δ 138.9; 138.8, 138.6, 138.5, 138.4, 138.1, 128.6, 128.4, 128.3, 128.2, 128.14, 128.11, 128.0, 127.75, 127.73, 127.6, 127.5, 127.4, 127.3, 126.6, 103.7, 102.9, 101.4, 82.9, 81.8, 81.2, 79.7, 78.8, 77.6, 75.8, 75.3, 75.15, 75.10, 73.6, 73.0, 71.6, 68.9, 68.3, 68.1, 66.4, 51.0; MALDI TOF MS (positive mode): calcd for C56H59N3NaO11 [M + Na]+ m/z, 972.41; found, 972.491.
:
11, v/v) to give 8 as a white floppy solid (1.42 g, 70.9%). 1H NMR (400 MHz, CDCl3): δ 7.45–7.20 (m, 30H, ArH), 5.01 (d, J = 11.3 Hz, 1H, CH2Ph), 4.92 (d, J = 11.3 Hz, 1H, CH2Ph), 4.84–4.66 (m, 6H, CH2Ph), 4.56 (d, J = 12.2 Hz, 1H, CH2Ph), 4.50–4.38 (m, 6H, H-1, H-1′, H-4′, CH2Ph), 4.10–3.94 (m, 4H, H-4, H-6b, H-6a′, OCH2CH2N3), 3.82 (dd, J = 10.5, 4.1 Hz, 1H, H-6b′), 3.76–3.57 (m, 4H, H-2, H-3′, H-6a, OCH2CH2N3), 3.55–3.32 (m, 6H, H-2′, H-3, H-5, H-5′, OCH2CH2N3); 13C NMR (100 MHz, CDCl3): δ 139.1; 138.7, 138.3, 138.2, 137.9, 128.6, 128.5, 128.4, 128.2, 128.1, 127.9, 127.8, 127.7, 127.66, 127.63, 127.3, 103.7, 102.6, 82.8, 81.8, 81.2, 79.4, 77.4, 76.6, 75.4, 75.3, 75.1, 73.6, 73.2, 72.1, 68.5, 68.3, 68.2, 66.2, 51.0; HRMS (ESI TOF): calcd for C56H61N3NaO11 [M + Na]+ m/z, 974.4204; found, 974.4194.
:
11, v/v) to give 4 (1.34 g, 75%) as colorless syrup. [α]25D = +22.1° (c 2.0, CHCl3). 1H NMR (600 MHz, CDCl3): δ 7.72–7.69 (m, 2H, ArH), 7.67–7.64 (m, 1H, ArH), 7.60–7.50 (m, 5H, ArH), 7.49–7.45 (m, 1H, ArH), 7.39–7.34 (m, 5H, ArH), 7.28–7.11 (m, 9H, ArH), 7.08–7.05 (m, 3H, ArH), 7.00–6.97 (m, 2H, ArH), 5.59 (d, J = 10.3 Hz, 1H, H-1), 5.44 (t, J = 8.8 Hz, 1H, H-2′), 5.38 (s, 1H, CHPh), 5.30 (s, 1H, CHPh), 4.89 (dd, J = 10.3, 3.7 Hz, 1H, H-3), 4.80 (d, J = 8.1 Hz, 1H, H-1′), 4.67 (t, J = 10.3 Hz, 1H, H-2), 4.52 (d, J = 13.2 Hz, 1H, CH2Ph), 4.48–4.46 (m, 1H, H-4), 4.42 (d, J = 13.2 Hz, 1H, CH2Ph), 4.32 (d, J = 11.7 Hz, 1H, H-6b), 4.07 (d, J = 2.9 Hz, 1H, H-4′), 3.98 (d, J = 12.5 Hz, 1H, H-6a), 3.79 (d, J = 11.7 Hz, 1H, H-6b′), 3.63–3.57 (m, 2H, H-5, H-6a′), 3.54 (dd, J = 9.5, 2.9 Hz, 1H, H-3′), 3.19 (s, 1H, H-5), 2.27 (s, 3H, SPhCH3); 13C NMR (150 MHz, CDCl3): δ 168.6, 166.8, 164.9, 137.9, 137.8, 137.7, 133.8, 133.7, 133.5, 132.8, 131.7, 131.5, 129.6, 129.4, 129.1, 128.6, 128.3, 128.2, 127.9, 127.6, 127.5, 126.8, 126.6, 123.3, 123.0, 101.5, 101.1, 100.0, 99.9, 83.0, 82.9, 77.2, 75.2, 73.1, 73.0, 72.6, 70.7, 70.5, 70.2, 69.3, 68.7, 66.7, 50.6, 21.2; HRMS (ESI TOF): calcd for C55H49NNaO12S [M + Na]+ m/z, 970.2873; found, 970.2879.
:
11, v/v) to afford 6 (1.2 g, 58%, colorless syrup as the only trisaccharide). [α]25D = +26.7° (c 1.2, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.47–7.40 (m, 4H, ArH), 7.38–7.15 (m, 38H, ArH), 6.83–6.78 (m, 2H, ArH), 5.32 (s, 1H, CHPh), 5.13 (d, J = 3.2 Hz, 1H, H-1′′), 5.09 (d, J = 11.3 Hz, 1H, CH2Ph), 4.89 (d, J = 11.3 Hz, 1H, CH2Ph), 4.84–4.82 (m, 1H, CH2Ph), 4.81–4.79 (m, 2H, CH2Ph), 4.78–4.75 (m, 2H, CH2Ph), 4.74–4.71 (m, 1H, CH2Ph), 4.70–4.68 (m, 1H, CH2Ph), 4.89 (dd, J = 11.3, 9.7 Hz, 2H, CH2Ph), 4.51–4.46 (m, 3H, H-1′, H-6b′′, CH2Ph), 4.42 (d, J = 8.1 Hz, 1H, H-1), 4.37 (d, J = 11.3 Hz, 1H, CH2Ph), 4.32 (d, J = 11.3 Hz, 1H, CH2Ph), 4.23 (d, J = 11.3 Hz, 1H, CH2Ph), 4.20–4.09 (m, 2H, H-4′′, H-6b′), 4.07–3.93 (m, 5H, H-2′′, H3′′, H-4, H-4′, OCH2CH2N3), 3.87–3.78 (m, 1H, H-6a′′), 3.76 (s, 3H, OCH3), 3.74–3.38 (m, 11H, H-2′ H-3, OCH2CH2N3, H-5′′, H-6b, H-2, H-5′, H-3′, H6a′, OCH2CH2N3), 3.37–3.27 (m, 2H, H-6a, H-5); 13C NMR (100 MHz, CDCl3): δ 159.3, 139.1, 138.6, 138.5, 138.4, 138.2, 130.8, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.7, 127.6, 127.5, 127.4, 127.0, 126.4, 113.6, 103.6, 103.1, 101.0, 100.8, 82.4, 81.7, 81.3, 78.6, 75.7, 75.4, 75.2, 75.1, 74.9, 73.8, 73.1, 71.9, 71.3, 69.3, 68.3, 68.1, 67.2, 62.9, 55.2, 51.0; MALDI TOF MS (positive mode): calcd for C84H89N3NaO17 [M + Na]+ m/z, 1435.62; found, 1435.20; and HRMS (ESI TOF): calcd for C84H89N3NaO17 [M + Na]+ m/z, 1434.6090; found, 1434.6093.
:
1, 12 mL) was stirred at 0 °C for 1 h, it was poured into saturated aq. NaHCO3 solution (50 mL). The mixture was extracted with CH2Cl2 (3 × 10 mL), and the organic payer was washed with saturated aq. NaHCO3 solution (3 × 10 mL) and water (50 mL), dried over Na2SO4, and then concentrated in vacuum. The crude product was purified with silica gel column chromatography (acetone–hexane 1
:
11, v/v) to give 20 (790 mg, 86.3%) as colorless syrup. [α]25D = +16.5° (c 1.73, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.43–7.37 (m, 4H, ArH), 7.36–7.28 (m, 20H, ArH), 7.27–7.19 (m, 16H, ArH), 5.38 (s, 1H, CHPh), 5.19 (d, J = 3.7 Hz, 1H, H-1′′), 5.06 (d, J = 11.7 Hz, 1H, CH2Ph), 4.89 (d, J = 11.0 Hz, 1H, CH2Ph), 4.86 (d, J = 11.7 Hz, 1H, CH2Ph), 4.81–4.75 (m, 3H, CH2Ph), 4.71 (t, J = 11.0 Hz, 2H, CH2Ph), 4.65 (d, J = 12.5 Hz, 1H, CH2Ph), 4.59 (d, J = 12.5 Hz, 1H, CH2Ph), 4.54 (d, J = 11.7 Hz, 1H, CH2Ph), 4.48 (d, J = 7.30 Hz, 1H, H-1), 4.42 (d, J = 7.30 Hz, 1H, H-1′), 4.38 (d, J = 12.5 Hz, 1H, CH2Ph), 4.31 (d, J = 11.7 Hz, 1H, CH2Ph), 4.25 (d, J = 11.7 Hz, 1H, CH2Ph), 4.19–4.14 (m, 1H, H-6a′′), 4.13–4.07 (m, 3H, H-4′, H-4′′, OCH2CH2N3), 4.06–4.01 (m, 2H, H-4, H-3′′), 3.97 (t, J = 9.5 Hz, 1H, H-2′′), 3.83 (dt, J = 11.7, 3.7 Hz, 2H, H-6b′′, H-6b′), 3.75–3.67 (m, 2H, H-6a′, OCH2CH2N3), 3.62 (t, J = 9.5 Hz, 1H, H-2′), 3.59–3.62 (m, 2H, H-5′′, H-6b), 3.51–3.38 (m, 6H, H-2, H-3, H-5′, H-3′, OCH2CH2N3), 3.35–3.29 (m, 2H, H-6a, H-5); 13C NMR (125 MHz, CDCl3): δ 139.3, 138.6, 138.4, 138.3, 138.2, 138.1, 137.7, 129.0, 128.5, 128.46, 128.40, 128.3, 128.2, 128.17, 128.14, 128.12, 127.9, 127.7, 127.66, 127.61, 127.59, 127.55, 127.2, 127.1, 126.3, 103.6, 102.9, 100.9, 100.3, 82.6, 81.7, 81.3, 78.7, 76.8, 76.4, 75.12, 75.10, 74.98, 74.92, 74.0, 73.8, 73.17, 73.13, 72.9, 72.1, 69.2, 68.7, 68.4, 68.1, 67.2, 62.8, 51.0; MALDI TOF MS (positive mode): calcd for C76H81N3NaO16 [M + Na]+ m/z, 1315.47; found, 1316.402; and HRMS (ESI TOF): calcd for C76H81N3NaO16 [M + Na]+ m/z, 1314.5515; found, 1314.5515.
:
9, v/v) to afford 3 (530 mg, 64.6%) as colorless syrup. [α]25D = +6.8° (c 0.8, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.70 (d, J = 6.8 Hz, 2H, ArH), 7.62–7.58 (m, 2H, ArH), 7.53–7.49 (m, 2H, ArH), 7.44–7.19 (m, 44H, ArH), 7.15–7.02 (m, 12H, ArH), 6.92 (d, J = 7.8 Hz, 2H, ArH), 5.55–5.47 (m, 1H), 5.46 (s, 1H, CHPh), 5.44 (s, 1H, CHPh), 5.43 (d, J = 7.8 Hz, 1H, H-1′′′′), 5.33 (s, 1H, CHPh), 5.02 (d, J = 10.8 Hz, 1H, CH2Ph), 4.97 (d, J = 3.9 Hz, 1H, H-1′′), 4.94 (d, J = 11.7 Hz, 1H, CH2Ph), 4.90 (d, J = 11.7 Hz, 1H, CH2Ph), 4.86 (d, J = 7.80 Hz, 1H, H-1′′′), 4.84 (d, J = 7.80 Hz, 1H, H-1′), 4.83 (d, J = 11.7 Hz, 1H, CH2Ph), 4.79 (d, J = 10.8 Hz, 1H, CH2Ph), 4.77 (d, J = 11.7 Hz, 1H, CH2Ph), 4.75 (d, J = 10.8 Hz, 1H, CH2Ph), 4.73 (d, J = 10.8 Hz, 1H, CH2Ph), 4.71 (d, J = 11.7 Hz, 1H, CH2Ph), 4.56 (d, J = 12.7 Hz, 1H, CH2Ph), 4.54 (d, J = 11.7 Hz, 1H, CH2Ph), 4.52 (d, J = 12.7 Hz, 1H, CH2Ph), 4.48 (d, J = 12.7 Hz, 1H, CH2Ph), 4.46 (d, J = 11.7 Hz, 1H, CH2Ph), 4.45 (d, J = 7.8 Hz, 1H, H-1), 4.40–4.31 (m, 3H), 4.29–4.26 (m, 1H), 4.25–4.23 (m, 1H), 4.19–4.17 (m, 1H), 4.16–4.05 (m, 4H), 4.04–3.92 (m, 4H), 3.91–3.80 (m, 4H), 3.78–3.70 (m, 3H), 3.69–3.38 (m, 9H), 3.32–3.20 (m, 4H), 2.87–2.84 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 168.6, 167.0, 164.9, 139.1, 138.7, 138.6, 138.3, 138.3, 138.26, 138.23, 138.0, 137.9, 137.8, 137.7, 133.4, 133.2, 132.6, 131.5, 131.4, 129.7, 129.6, 129.1, 128.7, 128.6, 128.4, 128.32, 128.30, 128.2, 128.1, 128.0, 127.9, 127.83, 127.80, 127.7, 127.6, 127.58, 127.51, 127.3, 127.1, 126.7, 126.4, 126.2, 122.8, 103.6, 103.3, 101.5, 100.9, 100.2, 99.9, 98.9, 82.2, 81.8, 81.4, 78.8, 77.3, 77.2, 75.4, 75.3, 75.2, 75.0, 74.9, 74.88, 74.81, 74.3, 73.5, 73.3, 73.1, 72.8, 72.1, 71.9, 70.8, 69.2, 69.0, 68.8, 68.4, 68.1, 67.3, 66.7, 66.1, 63.2, 52.6, 51.0; MALDI TOF MS (positive mode): calcd for C124H122 N4NaO28 [M + Na]+ m/z, 2139.310; found, 2138.771; and HRMS (ESI TOF): calcd. for C124H122 N4NaO28 [M + Na]+ m/z, 2137.8143; found, 2137.8213.
:
7, v/v) to give 21 as a white solid (240 mg, 54%). [α]25D = +14.6° (c 0.53, CHCl3). 1H NMR (600 MHz, CDCl3): δ 7.52–7.45 (m, 6H, ArH), 7.39–7.18 (m, 48H, ArH), 7.13 (d, J = 7.3 Hz, 2H, ArH), 5.56 (d, J = 6.6 Hz, 1H, –NHAc), 5.52 (s, 1H, CHPh), 5.43 (s, 1H, CHPh), 5.41 (s, 1H, CHPh), 5.11 (d, J = 3.2 Hz, 1H, H-1′′), 4.99 (d, J = 11.0 Hz, 1H), 4.93 (d, J = 8.1 Hz, 1H, H-1′′′′), 4.88 (s, 1H), 4.87 (s, 1H), 4.84–4.71 (m, 7H), 4.65 (s, 1H), 4.63 (s, 1H), 4.55 (d, J = 11.7 Hz, 1H), 4.50 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 6.9 Hz, 1H, H-1′′′), 4.40 (d, J = 7.3 Hz, 1H, H-1′), 4.39–4.33 (m, 3H), 4.29–4.22 (m, 3H, J = 7.3 Hz, H-1), 4.14–3.92 (m, 11H), 3.87 (d, J = 11.7 Hz, 1H), 3.82–3.65 (m, 4H), 3.63–3.57 (m, 3H), 3.55–3.34 (m, 6H), 3.33–3.26 (m, 3H), 2.92 (s, 1H), 1.53 (s, 3H, NHAc); 13C NMR (150 MHz, CDCl3): δ 171.7, 139.3, 138.6, 138.4, 138.1, 137.8, 129.0, 128.8, 128.5, 128.4, 128.3, 128.1, 127.8, 127.6, 127.1, 126.6, 126.3, 126.2, 104.6, 103.5, 103.1, 101.1, 100.9, 100.7, 100.6, 100.4, 82.0, 81.6, 81.3, 78.9, 78.5, 76.4, 75.7, 75.3, 75.1, 74.9, 74.3, 74.0, 73.5, 73.1, 72.9, 72.0, 71.6, 69.8, 69.3, 69.1, 68.4, 68.0, 67.1, 66.6, 63.1, 53.9, 51.0, 23.4; MALDI TOF MS (positive mode): calcd for C111H118N4NaO26 [M + Na]+ m/z, 1947.140; found, 1947.341; and HRMS (ESI TOF): calcd for C111H118N4NaO26 [M + Na]+ m/z, 1945.7932; found, 1945.8005.
:
6, v/v) to give 22 (192 mg, 70%) as colorless syrup. [α]25D = +29.1° (c 2.66, CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.56–7.49 (m, 3H), 7.46 (d, J = 7.3 Hz, 2H), 7.43–7.12 (m, 65H), 5.60 (d, J = 3.7 Hz, 1H, H–1′′′′′), 5.56 (d, J = 7.9 Hz, 1H, –NHAc), 5.51 (s, 1H), 5.45 (s, 1H), 5.39 (s, 1H), 5.13 (d, J = 3.1 Hz, 1H, H-1′′), 5.09 (d, J = 8.1 Hz, 1H, H-1′′′′), 5.03 (d, J = 11.6 Hz, 1H), 4.91 (d, J = 11.0 Hz, 2H), 4.87–4.75 (m, 6H), 4.74–4.56 (m, 7H), 4.55–4.41 (m, 7H, H-1′′′, H-1′, H-1), 4.38 (d, J = 12.2 Hz, 1H), 4.35–4.28 (m, 3H), 4.21–4.15 (m, 2H), 4.14–3.80 (m, 14H), 3.78–3.68 (m, 3H), 3.67–3.36 (m, 12H), 3.35–3.26 (m, 4H), 2.93 (s, 1H), 1.44 (s, 3H, –NHAc), 0.72 (d, J = 6.1 Hz, 3H, H-6′′′′′); 13C NMR (125 MHz, CDCl3): δ 170.9, 139.3, 139.1, 139.0, 138.8, 138.6, 138.5, 138.4, 138.3, 138.2, 138.1, 137.7, 129.0, 128.9, 128.7, 128.4, 128.37, 128.31, 128.27, 128.2, 128.04, 128.0, 127.9, 127.8, 127.6, 127.5, 127.4, 127.3, 127.2, 127.1, 126.6, 126.5, 126.2, 103.5, 102.1, 101.0, 100.9, 100.8, 100.7, 100.6, 96.3, 82.0, 81.7, 81.3, 79.0, 78.1, 77.4, 77.2, 75.9, 75.8, 75.5, 75.1, 74.9, 74.7, 74.5, 74.0, 73.5, 73.2, 73.1, 72.9, 72.8, 72.7, 72.14, 72.09, 72.02, 70.8, 70.5, 69.3, 69.2, 68.4, 68.0, 67.2, 66.6, 6.4, 66.1, 63.1, 54.6, 51.0, 23.4, 16.1; MALDI TOF MS (positive mode): calcd for C138H146N4NaO30 [M + Na]+ m/z, 2363.640; found, 2364.063; and HRMS (ESI TOF): calcd for C138H146N4NaO30 [M + Na]+ m/z, 2361.9920; found, 2361.9929.
:
1, 5 mL) was heated at 60 °C for 12 h, at which point MALDI TOF MS [positive mode: calcd for C138H146N4O30 [M + Na]+ m/z, 2099.3; found, 2100.4] confirmed the removal of all benzylidene groups. The solvent was removed in vacuum and the residue was co-evaporated with toluene 5 times to afford a solid product, which was briefly purified by passing through a short silica gel column with n-hexane and ethyl acetate (2
:
1 to 1
:
2) as the eluent. The product (30.0 mg, 14 μmol) was mixed with 10% Pd–C (20.0 mg) in MeOH and H2O (4
:
1, 10 mL), and the mixture was shaken under a H2 atmosphere at 50 psi for 48 h. The catalyst was removed by filtration through a Celite pad and the pad was subsequently washed with a mixture of MeOH and H2O (1
:
1). The combined filtrate was concentrated under vacuum and the residue was dissolved in 2 mL of H2O and lyophilized to provide the crude product, which was purified twice with a sephadex G-25 gel filtration column using water as the eluent followed by lyophilization to afford 2 (16.2 mg, 50%) as a white solid. [α]25D = +9.8° (c 0.4, H2O). 1H NMR (600 MHz, D2O): δ 5.04 (d, J = 3.7 Hz, 1H, H-1′′′′′), 4.70 (d, J = 2.9 Hz, 1H, H-1′′), 4.43 (d, J = 7.3 Hz, 1H, H-1′′′′), 4.38–4.34 (m, 2H, H-1′′′, H-1), 4.33 (d, J = 7.3 Hz, 1H, H-1′), 4.23–4.18 (m, 1H), 4.07–4.02 (m, 2H), 3.97–3.90 (m, 2H), 3.86–3.69 (m, 7H), 3.68–3.63 (m, 3H), 3.62–3.38 (m, 19H), 3.19 (d, J = 8.1 Hz, 1H), 3.10–3.06 (m, 2H), 1.86 (s, 3H, –NHAc), 1.03 (d, J = 6.6 Hz, 3H, H-6′′′′′); 13C NMR (125 MHz, D2O): δ 174.2, 103.9, 103.2, 102.0, 101.8, 100.4, 99.2, 78.6, 78.2, 77.1, 76.3, 76.0, 75.4, 75.0, 74.7, 74.5, 74.2, 73.5, 72.7, 72.0, 71.8, 70.8, 70.1, 69.4, 69.1, 69.0, 68.4, 68.0, 67.7, 66.7, 65.7, 60.9, 60.8, 60.3, 58.9, 51.6, 39.3, 22.2, 15.2; MALDI TOF MS (positive mode): calcd for C40H70N2NaO30 [M + Na]+ m/z, 1081.98; found, 1081.991; and HRMS (ESI TOF): calcd for C40H71N2O30 [M + H]+ m/z, 1059.4092; found, 1059.4089.
Footnote |
| † Electronic supplementary information (ESI) available: Additional experimental procedures for the synthesis of compounds 11, 8, 4, and 15, and NMR and MS spectra for all of the isolated intermediates and products. See DOI: 10.1039/c5ra00759c |
| This journal is © The Royal Society of Chemistry 2015 |